14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BMRA vs BWAY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Brainsway Ltd. (BWAY) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas BWAY carries 33.8/100 (SELL) at $9.34 (17.9x Forward P/E, 12.5% operating margin).
Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. BWAY 33.8/100 SELL), BWAY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (12.5% vs. -125.2% operating margin) and revenue trajectory (+35.4% vs. -8.3% YoY).
Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile BWAY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BMRA vs BWAY. Trailing 12-month operating profitability (BMRA -125.2% vs BWAY 12.5%) and valuation multiples (BMRA N/M vs BWAY 17.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $412.6M market capitalization and 12.5% operating margin.
OpEx & R&D Reinvestment62.8% of Rev ($68M)
90D Engineering Disclosures0 Published
Investor FAQ BMRA vs BWAY Key Questions & Quantitative Answers
As of Nov 16, 2026, Brainsway Ltd. (BWAY) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas BWAY carries 33.8/100 (SELL) at $9.34 (17.9x Forward P/E, 12.5% operating margin). Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. BWAY 33.8/100 SELL), BWAY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (12.5% vs. -125.2% operating margin) and revenue trajectory (+35.4% vs. -8.3% YoY). Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile BWAY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BWAY leads the Growth & Scale pillar: BMRA posts -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin), compared with BWAY at +35.4% YoY revenue growth and +59.8% YoY earnings growth on $108M TTM revenue (75.3% gross margin, 12.5% operating margin). On trailing 12-month operating scale, BMRA generates $4.3M in USD-normalized revenue versus $108M for BWAY. In operating R&D and SG&A reinvestment, BMRA deploys N/A (0 90-day corporate R&D disclosures) versus 62.8% of Rev ($68M) (0 disclosures) for BWAY.
BWAY screens cheaper on headline valuation multiples. BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin), whereas BWAY trades at 17.9x Forward P/E, 42.7x Trailing P/E, N/M PEG, and 3.8x EV/Revenue (14.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMRA (-113.8% ROE) versus BWAY (12.8% ROE) capital efficiency.
In options market volatility and institutional positioning, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk). By comparison, BWAY carries 111.0% implied volatility (77th %ile, Elevated (60th–80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.86β · 67% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.